

Date: 16 August 2018

**Re: Freedom of Information Request
Ref: 156-2018**

Thank you for your email dated 20th July 2018, requesting information regarding treatment figures.

The information that you require is as follows:

NB1: We only record stage at presentation to CCC; therefore if a patient presented with early disease and then went on to progress we would not capture these patients. Below figures are all based on patients presenting with stage III or IV disease only

NB2: A patient can fall into more than 1 year group e.g. they could receive treatment in both Dec 16 and Jan 17, and therefore be counted twice.

1. Please could you kindly provide the total number of patients treated for locally advanced or metastatic non-small cell lung cancer at your hospital/trust during: **(SACT only)**

- a. January 1st 2016 to December 31st 2016 = **472**
- b. January 1st 2017 to December 31st 2017 = **540**
- c. January 1st 2018 – 28th July 2018 = **409**

2. Please could you kindly provide the total number of patients who received the following treatments for the indications specified below, during:

- Pembrolizumab for untreated metastatic non-small-cell lung cancer

- a. January 1st 2016 to December 31st 2016 = **2**
- b. January 1st 2017 to December 31st 2017 = **47**
- c. January 1st 2018 – 28th July 2018 = **66**

- **Pembrolizumab for treating non-small-cell lung cancer after chemotherapy**
 - a. January 1st 2016 to December 31st 2016 = **0**
 - b. January 1st 2017 to December 31st 2017 = **106**
 - c. January 1st 2018 – 28th July 2018 = **81**

- **Nivolumab for previously treated locally advanced or metastatic NON-SQUAMOUS non-small-cell lung cancer**
 - a. January 1st 2016 to December 31st 2016 = **1**
 - b. January 1st 2017 to December 31st 2017 = **5**
 - c. January 1st 2018 – 28th July 2018 = **2**

- **Nivolumab for previously treated locally advanced or metastatic SQUAMOUS non-small-cell lung cancer**
 - a. January 1st 2016 to December 31st 2016 = **14**
 - b. January 1st 2017 to December 31st 2017 = **7**
 - c. January 1st 2018 – 28th July 2018 = **15**

- **Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy**
 - a. January 1st 2016 to December 31st 2016 = **0**
 - b. January 1st 2017 to December 31st 2017 = **0**
 - c. January 1st 2018 – 28th July 2018 = **6**

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could take a couple of minutes to complete a short feedback form via the link below:

<https://www.surveymonkey.co.uk/r/H39RFMM>